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We are delighted to announce the launch of Molecular
Autism - a new open-access journal published by BioMed
Central. Autism and associated conditions are now rec-
ognized as major disabilities with major implications for
the public purse. A recent economic analysis of the total
annual cost of autism in the UK estimated this to be £28
billion, assuming a prevalence of 1% of the population [1].
The social and communication deficits in this spectrum
of conditions, as well as the strongly repetitive behaviors
and unusual narrow interests, have their basis in neu-
rodevelopmental changes caused, at the most fundamen-
tal level, by molecular alterations, some of which have
been identified. The scope of Molecular Autism reflects
this broad perspective, from molecular to cellular to sys-
tems to neural, cognitive and behavioral level analyses,
and back again [2].
Molecular Autism joins other journals targeting autism
and associated conditions but differs in key ways. First,
Molecular Autism is both online and open access. In a
field where dissemination of accurate information has
become so important, where internationally, scientists,
educators, clinicians, and families are tracking the devel-
opments and are looking for up-to-date, definitive and
accessible sources of scientific information, Molecular
Autism will provide such a forum. Open access means
that the articles are freely available to all, worldwide, and
at no cost to the reader. Online publication also allows for
no restriction on number or length of articles and for the
inclusion of all available digital technologies: large data
sets, unlimited use of color, slide shows, animation, video
clips, and links to other web pages, all at no additional
charge. Articles are published online on the day of accep-
tance and, very soon after, are listed in bibliographic data-
bases and full-text article repositories [3]. BioMed
Central is a leader in online, open access journals ensur-
ing that this mission will be seamless.
Publication costs in subscription journals are paid by
the reader; in Molecular Autism these costs are defrayed
by the author via article processing charges (APCs). How-
ever, APCs can typically be covered by grants. In addi-
tion, individual APCs are waived in institutions that have
full membership to BioMed Central. A discounted APC is
provided for institutions with supporting membership
and authors from countries in low or low-middle income
categories defined by the World Bank may also have APC
charges waived. Beyond this, we will also consider indi-
vidual waivers on a case-by-case basis, making every
effort to ensure that lack of funds does not impede the
overall objective of publishing the best science, irrespec-
tive of authorship or country of origin [4].
The second way in which Molecular Autism differs
from other journals in the autism science field is by hav-
ing a focus on the molecular level. Whereas other jour-
nals have a broad remit, from clinical and educational
psychological studies through cognitive experiments to
neuroimaging and genetics, Molecular Autism will pub-
lish articles that have a bearing on the molecular basis of
autism and related conditions. This does not preclude a
behavioural or cognitive or neural study, so long as there
is also a molecular measure in the study or the implica-
tions for the molecular basis of autism are considered.
Our reason for this requirement is that part of our mis-
sion statement is to accelerate research into the funda-
mental determinants of the condition [2]. The first 60
years of autism research have had a bias towards the psy-
chological, and we intend - via this new journal - to cor-
rect this emphasis.
The third way in which Molecular Autism differs from
other autism journals is that it aims to achieve integration
across the multiple levels that these syndromes affect. We
now recognize that autism will not be understood by a
single discipline, be it genetics or neurology or psychol-
ogy. Rather, each level has to be mapped on to the next, to
reveal how mechanisms give rise to the phenotype within
each system. This makes autism and related syndromes
complex but the response to such a challenge has to be
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We are committed to publishing the highest quality
articles in the field. Since we made our first call for manu-
scripts, we have attracted manuscripts from leaders in the
field and have sustained a constant rate of submissions.
Articles in Molecular Autism are peer-reviewed by at
least two, and most typically more, experts, drawn from
the Editorial Board and the wider scientific community.
Manuscript review and processing is rapid while, with the
assistance of the Editorial Board, we shall ensure that the
highest standards are maintained, including fair referee-
ing and editorial decision-making [5].
Molecular Autism is also a forum for timely reviews of
topics of interest and will be a site for discussion of open
questions in the field. After the launch of the journal, we
will review the state-of-the-art in association studies in
psychiatric genetics and define the criteria for the highest
quality studies, and will commit to this level of rigor in all
articles published in Molecular Autism.
We are in a transformative period in autism research.
Behavioral interventions have been shown to be effective,
and earlier diagnosis, using molecular and behavioral
methods, becomes critical to take advantage of these
interventions. In parallel, identification of etiological
causes of autism has led to novel drug targets, and several
large-scale clinical trials are being carried out based on
these findings. We underline the important ethical issue
that research into efficacy of medications should evaluate
not only improvements in areas of known disability, but
the lack of unwanted side-effects (particularly ensuring
that areas of strength in autism are not compromised).
Molecular Autism will be at the forefront of these break-
throughs.
Author Details
1Seaver Autism Center for Research and Treatment, Departments of Psychiatry, 
Neuroscience, and Genetics and Genomic Sciences, Mount Sinai School of 
Medicine, New York, NY 10029, USA and 2Autism Research Centre, Department 
of Psychiatry, University of Cambridge, Cambridge, CB2 8AH, UK
References
1. Knapp M, Romeo R, Beecham J: Economic cost of autism in the UK.  
Autism 2009, 13:317-336.
2. About Molecular Autism   [http://www.molecularautism.com/info/about/
]
3. What is open access?   [http://www.molecularautism.com/info/faq/
?question=openaccess]
4. Frequently asked questions about BioMed Central's article processing 
charges   [http://www.biomedcentral.com/info/authors/apcfaq]
5. Molecular Autism Editorial Board   [http://www.molecularautism.com/
edboard/]
doi: 10.1186/2040-2392-1-1
Cite this article as: Buxbaum and Baron-Cohen, Molecular Autism: acceler-
ating and integrating research into neurodevelopmental conditions Molecu-
lar Autism 2010, 1:1
Received: 17 February 2010 Accepted: 22 February 2010 
Published: 22 February 2010
This article is available from: http://www.molecularautism.com/content/1/1/1© 2010 Buxbaum nd Baron-Cohen; licensee BioMed Central Ltd. is an Open Access article distributed und r the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Molecular Autis  2010, 1:1
